Cancer atlas reveals how tumours evolve inside the body
A massive undertaking to map cancer tumours is providing new insights into how the disease forms, evolves and develops resistance to treatments
A massive undertaking to map cancer tumours is providing new insights into how the disease forms, evolves and develops resistance to treatments
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
Innovent Biologics will license IBI3009, its investigational DLL3-targeted antibody–drug conjugate (ADC) for small cell lung cancer (SCLC), to Roche for $80 million upfront and payments…
Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests.
The Lung Cancer Research Foundation® (LCRF) has announced its 2024 Scientific Grant Program award will fund $3.55 million in new research in lung cancer.
The most promising approach uses mRNA.
An abstract is unavailable.
A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage…